Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Shionogi
Biotech
Shionogi's RSV antiviral reduces viral load in ph. 2 adult trial
Shionogi’s respiratory syncytial virus antiviral for adults has proven its ability to reduce viral load in a phase 2 trial.
James Waldron
Jan 30, 2025 5:32am
After FTC stalled Sanofi deal, Shionogi bags Maze's Pompe drug
May 10, 2024 5:02am
'We beg you': Biotechs plead for help with long COVID research
Feb 22, 2023 11:20am
Former AbbVie R&D chief tapped to run Tessera—Chutes & Ladders
Jun 3, 2022 9:30am
Shionogi splashes $100M on F2G's rare fungal disease drug
May 16, 2022 5:28am
Trevena COVID-19 treatment trial ceased due to early inferiority
Apr 25, 2022 4:25pm
